New Triple-Drug attack on breast cancer shows promise in Late-Stage trial

NCT ID NCT07207070

Recruiting now Disease control Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether adding a new oral drug called JS105 to two standard drugs (dalpiciclib and fulvestrant) can better control advanced breast cancer in people with a PIK3CA gene mutation. The study will enroll 312 adults with HR-positive, HER2-negative breast cancer that has returned or spread. Participants are randomly assigned to receive either the three-drug combo or the two-drug combo alone, and researchers will track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS105 (a drug taken by mouth) combined with dalpiciclib and fulvestrant
What this could lead to: If successful, this combination could offer a new treatment option that delays cancer progression in people with a specific genetic mutation (PIK3CA) and advanced breast cancer.
What could go wrong: This is a phase 3 trial, but it's still experimental. The added drug (JS105) may cause more side effects or not improve outcomes. Results may not apply to all breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Chinese Acadamy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100021, China
Henan Provincial Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.